Lb Pharmaceuticals Inc Quick Ratio (LBRX) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Lb Pharmaceuticals Inc  (NASDAQ: LBRX)

Lb Pharmaceuticals Inc's Quick Ratio

LBRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 7.03 below Lb Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 146 other companies have achieved higher Quick Ratio than Lb Pharmaceuticals Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 123, from total ranking in the second quarter 2026 at 1377.

Explain Quick Ratio?
How much Cash & cash equivalents LBRX´s has?
What are LBRX´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/LBRX/financial-strength
https://api.csimarket.com/api/v1/companies/LBRX/fundamentals
https://api.csimarket.com/api/v1/companies/LBRX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
LBRX Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 416.7 %
Y / Y Cash & cash equivalent Change -31.61 %
Quick Ratio MRQ 7.03
LBRX's Total Ranking # 123
Seq. Current Liabilities Change 26.71 %
Seq. Cash & cash equivalent Change -41.8 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 147
Healthcare Sector # 232
Overall Market # 635


Quick Ratio Statistics
High Average Low
53.15 19.57 3.01
(Sep 30 2025)   (Dec 31 2025)




Financial Statements
Lb Pharmaceuticals Inc's Current Liabilities $ 31 Millions Visit LBRX's Balance sheet
Lb Pharmaceuticals Inc's Cash & cash equivalent $ 215 Millions Visit LBRX's Balance sheet
Source of LBRX's Sales Visit LBRX's Sales by Geography


Cumulative Lb Pharmaceuticals Inc's Quick Ratio

LBRX's Quick Ratio for the trailling 12 Months

LBRX Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 367.51 %
Y / Y Cash & cash equivalent TTM Growth 184.32 %
Quick Ratio TTM 13.08
Total Ranking TTM # 2822
Seq. Current Liabilities TTM Growth 48.97 %
Seq. Cash & cash equivalent TTM Growth -9.2 %


On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $30.57 millions, cumulative Quick Ratio decreased to 13.08 below the Lb Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 404 other companies have achieved higher Quick Ratio than Lb Pharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2473 to 2822.

Explain Quick Ratio?
How much Cash & cash equivalents LBRX´s has?
What are LBRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 405
Healthcare Sector # 797
Within the Market # 2822


trailing twelve months Quick Ratio Statistics
High Average Low
21.94 21.94 21.94
(Mar 31 2026)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Relmada Therapeutics Inc  19.30 $ 202.123  Millions$ 10.474  Millions
Mbx Biosciences Inc   19.14 $ 481.594  Millions$ 25.167  Millions
Telomir Pharmaceuticals Inc   19.07 $ 4.516  Millions$ 0.237  Millions
Equillium Inc   18.92 $ 53.322  Millions$ 2.819  Millions
Onkure Therapeutics Inc   18.58 $ 163.305  Millions$ 8.789  Millions
Benitec Biopharma Inc   18.38 $ 176.368  Millions$ 9.594  Millions
Alto Neuroscience Inc   17.90 $ 319.344  Millions$ 17.836  Millions
Monopar Therapeutics Inc   17.65 $ 52.634  Millions$ 2.982  Millions
Canton Strategic Holdings Inc   17.50 $ 26.917  Millions$ 1.538  Millions
Upstream Bio Inc   17.34 $ 207.365  Millions$ 11.960  Millions
Siga Technologies Inc  17.27 $ 116.380  Millions$ 6.738  Millions
Neuphoria Therapeutics Inc   17.26 $ 18.744  Millions$ 1.086  Millions
Arrivent Biopharma inc   16.86 $ 393.691  Millions$ 23.357  Millions
Keros Therapeutics Inc   16.36 $ 259.464  Millions$ 15.858  Millions
Mira Pharmaceuticals Inc   16.36 $ 6.972  Millions$ 0.426  Millions
Design Therapeutics Inc   16.36 $ 208.608  Millions$ 12.753  Millions
Whitehawk Therapeutics Inc   16.25 $ 169.672  Millions$ 10.441  Millions
Palvella Therapeutics Inc   15.85 $ 236.680  Millions$ 14.928  Millions
Jade Biosciences Inc   15.70 $ 475.706  Millions$ 30.293  Millions
Avalo Therapeutics Inc   15.63 $ 392.966  Millions$ 25.135  Millions
Bioage Labs Inc   14.91 $ 283.637  Millions$ 19.027  Millions
Lisata Therapeutics Inc   14.89 $ 304.056  Millions$ 20.417  Millions
Damora Therapeutics Inc   14.72 $ 528.478  Millions$ 35.892  Millions
Sellas Life Sciences Group Inc   14.51 $ 134.711  Millions$ 9.286  Millions
Protagonist Therapeutics inc   14.42 $ 800.064  Millions$ 55.464  Millions
Praxis Precision Medicines Inc   14.20 $ 745.323  Millions$ 52.498  Millions
Tenax Therapeutics Inc   13.61 $ 113.700  Millions$ 8.355  Millions
Ensysce Biosciences Inc   13.56 $ 29.671  Millions$ 2.189  Millions
Corvus Pharmaceuticals Inc   13.25 $ 204.252  Millions$ 15.418  Millions
Erasca Inc   13.10 $ 643.696  Millions$ 49.122  Millions

Date modified: 2026-11-06T10:15:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.